BC Week In Review | Jul 20, 2015
Clinical News

AVX-001: Phase I/IIa data

A double-blind, dose-escalation Phase I/IIa trial in 26 patients with mild to moderate psoriasis showed that topical AVX001 for 4 weeks significantly reduced psoriasis plaque thickness vs. placebo. The maximum tolerated dose (MTD) was not...
BioCentury | Apr 8, 2013
Emerging Company Profile

Ziarco: Scratching the allergic itch

Ziarco Pharma Ltd. emerged last year from a shuttered Pfizer Inc. R&D site in Sandwich, U.K., with a quartet of allergy and inflammation assets that otherwise would have been shelved and forgotten. The biotech's lead...
Items per page:
1 - 2 of 2